Quick Summary
- Johnson & Johnson received FDA clearance for Icotyde, an oral plaque psoriasis medication co-developed with Protagonist Therapeutics (PTGX), triggering a ~4.69% drop in ABBV shares
- The once-daily oral formulation positions Icotyde as a direct challenger to AbbVie’s flagship immunology drug Skyrizi
- Wall Street analysts maintain optimistic Skyrizi sales projections, forecasting 23% revenue growth through FY2026
- Technical indicators show ABBV trading beneath its SMA-20 ($227.73), SMA-50 ($224.27), and hovering near its SMA-200 ($214.95), signaling bearish momentum
- The company set FY2026 EPS projections between $14.37 and $14.57, while unveiling a strategic antibody discovery collaboration with Alloy Therapeutics
Shares of AbbVie (ABBV) tumbled approximately 4.69% during Tuesday’s trading session following the Food and Drug Administration’s approval of Johnson & Johnson’s (JNJ) novel plaque psoriasis medication, Icotyde. The regulatory clearance spooked market participants who recognize Skyrizi’s critical importance to AbbVie’s growth strategy in the post-Humira era.
Developed through a partnership between J&J and Protagonist Therapeutics (PTGX), Icotyde represents a once-daily oral alternative for treating plaque psoriasis. This positions the medication as a head-to-head competitor with Skyrizi, which stands as AbbVie’s leading immunology asset and a cornerstone revenue generator.
However, Wall Street researchers maintain confidence in Skyrizi’s competitive position. The drug’s demonstrated effectiveness and administration schedule continue to be viewed as differentiating factors, with forecasts indicating a 23% revenue expansion for Skyrizi through fiscal year 2026.
Shares settled near $212.50 after launching the session below Monday’s $218.60 close. The trading range spanned from $209.42 to $218.60, demonstrating sustained selling momentum throughout the day.
Chart Analysis Points to Downward Pressure
From a technical standpoint, ABBV currently trades beneath its SMA-20 ($227.73), SMA-50 ($224.27), and marginally under its SMA-200 ($214.95). This positioning below all major moving averages signals clear bearish control.
Both daily and weekly Relative Strength Index measurements indicate sell signals. The Commodity Channel Index and Bollinger Band Position show oversold conditions with negative momentum. The Average Directional Index remains subdued, indicating the absence of a defined trend, while the MACD holds neutral territory.
Immediate support emerges at $210.83, and a breakdown through this level could accelerate downward movement. Overhead resistance appears at the Ichimoku Kijun line positioned at $227.58.
Traders are monitoring a potential range-bound opportunity between $210.83 and $215.22, with some market participants anticipating a bounce if price action consolidates near the lower boundary.
The SMA-200 at $214.95 might provide temporary support, though the balance of technical evidence continues to favor the bears.
Legacy Challenges and Portfolio Headwinds
The competitive pressure from Icotyde arrives during a challenging period for AbbVie. The pharmaceutical giant continues navigating the aftermath of Humira’s patent expiration, while its aesthetics division — featuring products like Juvederm — experiences persistent revenue contraction.
Several institutional investors have reduced their ABBV holdings in recent periods, reflecting evolving market sentiment toward the stock. Corporate insider transactions have tilted toward sales, with two selling events occurring over the past three months and zero purchase activity.
On a more constructive note, AbbVie revealed a multi-year strategic alliance with Alloy Therapeutics focused on advancing antibody discovery capabilities. The arrangement features upfront compensation and milestone-based payments, demonstrating ongoing commitment to research and development initiatives.
Management also released FY2026 earnings per share guidance ranging from $14.37 to $14.57, which some observers interpret as confidence in the company’s fundamental business trajectory.
The analyst community maintains a consensus price target of $251.44, accompanied by a recommendation score of 2.2 — indicating a moderate buy rating. Institutional ownership remains substantial at 74.71%.
According to GF Value analysis, ABBV carries an estimated fair value of $198.80, suggesting the stock trades near appropriate valuation levels at current prices.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
